Editas Medicine, Inc. (NASDAQ: EDIT) has announced positive initial clinical data from an ongoing, open label Phase I/II “BRILLIANCE” study EDIT-101, a CRISPR-based experimental treatment… Read More »Editas Medicine, Inc. (NASDAQ; EDIT) has announced positive clinical data on their CRISPR gene therapy product on LCA10
The US FDA (Food and Drug Administration) has approved authorisation for “Byooviz” (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) “for the treatment of… Read More »FDA approval announces the first biosimilar in the USA for ranibizumab (Lucentis) intravitreal injection in neovascular AMD, RVO and myopic CNV
Researchers at Taipei Medical University, Taiwan have reported on an association of retinal diseases and Parkinson’s disease (PD), including a potential reversal of the risk… Read More »An association of retinal diseases and Parkinson’s disease (PD) may reverse the risk following dopamine supplementation
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 13th, 2021 edition of EURETINA’s web-based digital magazine,… Read More »October 13th, 2021: “EURETINA-Brief”© Issue No. 244
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***